Spyre Therapeutics, Inc.
SYRE
$75.77
$0.730.97%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -179.44M | -155.20M | -148.97M | -206.81M | -208.93M |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -1.07M | -8.12M | -20.03M | 41.10M | 47.65M |
| Change in Net Operating Assets | -5.12M | -5.93M | 7.13M | 11.54M | -8.58M |
| Cash from Operations | -185.63M | -169.25M | -161.87M | -154.18M | -169.86M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | 0.00 | 0.00 | 7.00M | 7.00M | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -86.83M | -143.48M | -73.61M | -55.87M | -248.38M |
| Cash from Investing | -86.83M | -143.48M | -66.61M | -48.87M | -248.38M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 326.53M | 314.32M | 227.37M | 239.96M | 239.72M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | 0.00 | 0.00 | 0.00 |
| Repurchase of Preferred Stock | -- | -- | -- | -220.00K | -355.00K |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -5.37M | -5.30M | -5.56M | -499.00K | -499.00K |
| Cash from Financing | 321.16M | 309.03M | 221.81M | 239.24M | 238.87M |
| Foreign Exchange rate Adjustments | -- | -- | -15.00K | 1.00K | 1.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 48.69M | -3.70M | -6.68M | 36.19M | -179.38M |